Cimzia (certolizumab pegol injection, from UCB) has been approved by the FDA for the treatment of moderate-to-severe Crohn’s disease (CD) when conventional therapies have failed. This approval is based on clinical trials involving >1500 patients which showed a statistically significant greater number of CD patients achieved and sustained a clinical response with Cimzia for up to six months, compared to placebo. Cimzia was also effective in maintaining disease remission in a majority of patients without dose escalation.

Cimzia is a pegylated, humanized, anti-TNF-α (tumor necrosis factor-alpha) antibody expected to be available by the end of April 2008.

For more information call (770) 970-7500 or visit www.ucb-group.com.